clinical trial · NCT03075670
A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B
Novo Nordisk A/S·phase1·completed·n = 15
Congenital Bleeding DisorderHaemophilia BN9-GPALPROLIX®
brief summary
This trial is conducted in Europe and the United States of America. The aim of this trial is to compare the pharmacokinetics (the exposure of the trial drug in the body) of nonacog beta pegol (N9-GP) and ALPROLIX® in patients with haemophilia B.
started
Mar 7, 2017
primary completion
Dec 8, 2017
completion
Dec 8, 2017
last updated
May 26, 2023
official title
A Trial Comparing the Pharmacokinetics of Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol